Molecular structure of TAE684, CAS Number: 761439-42-3
TAE684 (CAS 761439-42-3)
See product citations (2)
Alternate Names:
5-Chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-2,4-pyrimidinediamine; NVP-TAE684
Application:
TAE684 is A selective NPM-ALK phosphorylation inhibitor which also inhibits ALK and LRRK2 Kinase
CAS Number:
761439-42-3
Purity:
>97%
Molecular Weight:
614.20
Molecular Formula:
C30H40ClN7O3S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
TAE684 selectively inhibits the phosphorylation of NPM-ALK, inducing apoptosis and G1 phase arrest in Ba/F3 cell lines. TAE684 potently inhibits the proliferation of Ba/F3 NPM-ALK cells with IC50 of 3 nM, without affecting the survival of Ba/F3 cells even at 1 μM. TAE684 also inhibits proliferation of NPM-ALK-expressing human ALCL cell lines including Karpas-299 and SU-DHL-1 with IC50 of 2–5 nM.
TAE684 (CAS 761439-42-3) References
- EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. | Koivunen, JP., et al. 2008. Clin Cancer Res. 14: 4275-83. PMID: 18594010
- Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. | Li, Y., et al. 2011. Neoplasia. 13: 1-11. PMID: 21245935
- Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells. | Tanizaki, J., et al. 2012. Br J Cancer. 106: 763-7. PMID: 22240786
- Small-molecule inhibitors of the c-Fes protein-tyrosine kinase. | Hellwig, S., et al. 2012. Chem Biol. 19: 529-40. PMID: 22520759
- Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. | Yamada, T., et al. 2012. Clin Cancer Res. 18: 3592-602. PMID: 22553343
- Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. | Tanizaki, J., et al. 2012. Clin Cancer Res. 18: 6219-26. PMID: 22843788
- A simple, highly visual in vivo screen for anaplastic lymphoma kinase inhibitors. | Rodrigues, FS., et al. 2012. ACS Chem Biol. 7: 1968-74. PMID: 22985331
- ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT. | Debruyne, DN., et al. 2016. Oncogene. 35: 3681-91. PMID: 26616860
- Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma. | Regairaz, M., et al. 2016. Am J Pathol. 186: 435-45. PMID: 26687816
- Anaplastic lymphoma kinase regulates binge-like drinking and dopamine receptor sensitivity in the ventral tegmental area. | Dutton, JW., et al. 2017. Addict Biol. 22: 665-678. PMID: 26752591
- Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC. | Dai, Y., et al. 2018. Radiat Oncol. 13: 1. PMID: 29304828
- Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). | Powell, CE., et al. 2018. J Med Chem. 61: 4249-4255. PMID: 29660984
- Tumour-derived substrate-adherent cells promote neuroblastoma survival through secreted trophic factors. | Li, J., et al. 2021. Mol Oncol. 15: 2011-2025. PMID: 33932101
Inhibitor of:
ALK, Atm, FAM150A, GRB7, HEB, IRS-2, K-cadherin, Krtap4-9, LRRK2, N-cadherin, SIP1, Twinkle, and Tyro3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TAE684, 5 mg | sc-364626 | 5 mg | $184.00 | |||
TAE684, 50 mg | sc-364626A | 50 mg | $969.00 |